Asset
Ozekibart
Inhibrx Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03715933 | phase1 | recruiting | 2018-10-08 | 2028-12-01 | Inhibrx Biosciences, Inc | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas |
| NCT04950075 | phase2 | active_not_recruiting | 2021-09-23 | 2025-09-30 | Inhibrx Biosciences, Inc | Study of INBRX-109 in Conventional Chondrosarcoma |
FDA applications (0)
This company has no applications containing this asset.